CAS No.: 608141-41-9
Purity: 99% (HPLC);
Packing information: 100g, 500g, 1KG.
Note: White solid.
On March 23, 2014, the FDA approved Celgene's Otezla (aprmilast) for the treatment of psoriatic arthritis. The main symptoms of psoriatic arthritis are joint pain, stiffness, and swelling. The currently approved treatments for psoriatic arthritis are corticosteroids, tumor necrosis factor TNF (Abbott Adamu) blockers and interleukin-12/interleukin-23 inhibitors, while Otezla (apremilast) is a phosphodiesterase 4 (PDE4) inhibitor. apremilast has a great advantage to analysts as well as its sales could reach $2 billion. Patients in the Otezla-treated group in clinical trials showed improvement in PsA signs and symptoms, including tenderness, joint swelling and physical function, compared with placebo.
3rd Floor, Building A7, No. 6 Factory Area, Lianyuan Road, Torch Development Zone, Zhongshan City
Tel:+86 0760-86925767 Fax：0760-86925770 Add:A7, No. 6, Lianyuan Road, Zhongshan Torch Development Zone